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Sociocultural Impact of AIDS Understanding on Accessibility to Vital Resources
Eden Lowinger, Briana Lopez-Patino, Dr. Sean Massey, Julia Haager
ABSTRACT
The first fifteen years of the AIDS Crisis (1981-1996) were characterized by an immense need by
those impacted both for legitimization of diagnoses and access to treatments which targeted both
the HIV virus itself and resulting opportunistic infections (OIs). However, early epidemiological
trends and the social perception that AIDS was a disease of white gay men resulted in much of
the initial focus to center this population and their experience of the disease. This contributed to
an incomplete understanding of the natural history of the virus, a failure to identify OIs more
common in women and IV drug users (IVDUs), and barriers to vital services. In addition, most
clinical trials-which were the only legal avenue to experimental treatments before 1989- excluded
or limited the participation of diverse populations. Among those who did have access to clinical
trials, as well as many others whose lives were directly affected by the epidemic, the cycles of
hope (as treatments emerged) and despair (as their ineffectiveness and toxicities were revealed)
was mentally and physically taxing, and in many cases fatal due to the limits of the therapy.

METHODS
The current investigation involves archival materials related to Gay Men’s Health Crisis
(GMHC) available in personal archived and the NYPL Special Collections, and articles (both
journalistic and medical) from the time. GMHC was the first and largest AIDS service
organization, formed in 1982 to address the expanding needs of people with AIDS (PWAs).
Deeply rooted in gay identity, the organization was conflicted in their responsibility to serve all
PWAs. Both oral history interviews with GMHC staff and volunteers conducted and/or
analyzed as part of this project and internal documents shed light on this tension. Source
material was analyzed to identify the obstacles associated with access to diagnoses, treatments,
and educational resources across differing risk groups of PWAs, including gay men, women,
and IV drug users.

CHANGING DEFINITION OF AIDS
Key:

OI commonly experienced in gay or bisexual men
OI commonly experienced in women
OI commonly experienced in IVDU
Little information found or uncommon OI

1987
A negative test ruled out an AIDS diagnosis, unless Pneumocystis carinii
pneumonia was present or the CD4 count was less than 400/mm^3
With a positive test:

If test is inconclusive:
Cryptosporidiosis
Cytomegalovirus
Kaposi’s Sarcoma

Mycobacterium avium
Extrapulmonary
Cryptococcosis

Pneumocystis
carinii pneumonia

Extrapulmonary TB

Toxoplasmosis

Wasting Syndrome

Herpes simplex virus

Salmonella septicemia
Esophageal candidiasis

How did exclusionary criteria within AIDS clinical trials limit access? How did the
changing treatment landscape impact the emotional toll on all PWAs?
Who was GMHC for? How did their organizational identity influence educational efforts
and the clients they served?

EARLY AIDS UNDERSTANDING: “GAY CANCER”
• CDC, 1981: labels of “Gay Cancer” and “Gay Related Immune Deficiency” show
the early perception of AIDS (termed in 1982) within a gay male context
• 1984: Multicenter AIDS Cohort Study begins, studying AIDS progression in nearly
5,000 gay men, 94-95% of whom are white
• 1993: Driven by lack of knowledge and pressure from activists, the CDC and the
NIAID initiate the Women’s Interagency HIV Study, the first of its scale
• The WIHS was much more diverse; 80% of cohort identified as Black, Latina, or
Hispanic
• Women included different risk groups than gay men: about half contracted HIV
through IV drug use, and about a third from heterosexual transmission
• Due to the near-decade space between these studies, however, vital data for women
was not collected in the early years. This led to an underdiagnosed population who
were unable to receive vital services such as Medicaid/insurance coverage and
disability benefits

EMERGING TREATMENTS: A STORY OF HOPE & DESPAIR
•
•
•
•
•

Until 1996, there was no long-term treatment for HIV/AIDS
PWAs had to act as their own medical advocates and navigate treatment options
AZT, the most popular AIDS drug, had a 2-year survival rate of only 47%
Many PWAs were distrustful of AZT and debated its efficacy
PWA Coalition Newsline writer Rob Schnick: “people who say AZT is no good don’t know

science from a hole in the ground.”
• AZT was extremely expensive: $8,000 a year in 1989. It wasn’t alone.
• Aerosolized Pentamidine, used to treat common OI Pneumocystis carinii pneumonia (PCP)
was a great expense as both the medicine and a nebulizer had to be purchased, with superior
nebulizers not covered by Medicaid
• By 1993, the Concorde trials more publicly exposed the limitations of AZT. AZT was highly
toxic, and pentamidine wasn’t without its risks, as it had the fatal potential to encourage PCP
spread in other parts of the body
• GMHC client describes being “overwhelmed by hopelessness and negative attitude [...] has

had a negative reaction to AZT and pentamidine aerosol”
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• Until 1989, participating in a clinical trials was the only way to access experimental AIDS
and OI therapies
• Exclusion of women and IVDUs resulted in disproportionately white and male trial
participants
• The first large-scale AZT and Aerosolized Pentamidine trials were almost exclusively men
• Under FDA guidelines, from 1977-1993, women of ‘child-bearing potential’ could not
participate in trials unless expensive fetal toxicity studies were conducted
• IVDUs were often excluded because they were seen as unreliable subjects. Also, lack of
clinical trial advertising and clinics centered in white neighborhoods limited IVDU access
• At the time of approval, no AZT trials had included IVDUs, resulting in the discovery of
serious adverse effects only after individuals had consumed the drug
• Even for white male PWAs, clinical trial access was limited by uncontrollable factors such
as extent of AIDS progression or use of other prescription medication
• PWAs in placebo trials didn’t know if they were receiving the drug, or if their AIDS was
being purposely left untreated

Isoporiasis
Pulmonary Candidiasis

Histoplasmosis

Brain Lymphoma

Non-Hodgkins Lymphoma

Progressive multifocal
leukoencephalopathy

AIDS-related dementia

RESEARCH QUESTIONS
How did the emergence of HIV/AIDS primarily among gay white men influence the early
investigation and understanding of the disease?

EXCLUSION FROM CLINICAL TRIALS, WHICH
WERE THE ONLY GLIMPSE OF HOPE

WE SERVE EVERYONE! WHO? HOW? WHY?
Who was GMHC for?
Former employee of GMHC’s Education Department James Holmes identified early
responses to AIDS were centered on gay men and didn’t consider other risk groups:

“It wasn’t that nuanced at that particular time. This was a crisis, people were dying [...] the
demographic of what the interest of GMHC was -at that time- was gay men.”

In 1990, the CDC
published an analysis
of death certificates
among women with
HIV/AIDS, finding
that HIV+ Black
women had an
incidence of mortality
nine times higher than
white women, and that
65% of women died
without an AIDS
diagnosis.

While the 1991
International AIDS
Conference was
taking place, the
AIDS Coalition To
Unleash Power
(ACT UP) published
this full-page ad in
the New York
Times.

The 1993 definition was more inclusive of women as it was the first to include
gynecological symptoms. As a result, the annual percent change in AIDS deaths
for women increased from approximately 11.5% in 1992-93 to 30% in 1993-94.
The criterion below assumed a positive HIV test and ranked symptoms, with only
the most severe (category “C”) allowing for an AIDS diagnosis.
AIDS Diagnosis Recommended in the
presence of conditions listed in 1987, and/or:
Cytomegalovirus Retinis
Persistent vulvovaginal candidiasis
Cervical dysplasia/ cervical carcinoma
Pelvic Inflammatory Disease

Struggles with inclusivity
Amber Hollibaugh, founder of the Lesbian AIDS Project (LAP) describes the difficulty in
convincing GMHC of its necessity. “There’s been a struggle in GMHC to deal with women’s
issues,” Hollibaugh identifies, which includes both staff and clientele. “You can’t serve
women the same way you serve gay men.” Beginning in 1992, the LAP sought to serve
lesbians where they were: “in prisons, in drug rehabilitation programs, in halfway homes, in

shelters…”
As expressed in focus groups which formed as a response to GMHC’s ambivalence with
diversity, educational services were not as accessible to women, IVDUs and people of color.
Black clients were concerned over lack of educational outreach in their neighborhoods, drug
users conveyed feelings of IVDU-phobia, women with children found GMHC’s event times
inconvenient, and nearly every group identified lack of transportation as a barrier to
GMHC’s services.

CONCLUSION

1993

New conditions of HIV+ women were
included in the “B” category.

When managed growth was implemented in 1992 as a means to cap the weekly client intakes
at 25, it was met with concern about how this would impact clientele demographics. In a
letter, client services volunteer Matt Baney expressed “a gay man should not be bumped for
someone else because his diagnosis came later in the month.” That “someone else” implied
IVDUs.

Invasive cervical cancer
Pulmonary TB
Recurrent Pneumonia
CD4 T- lymphocyte count <200
cells/uL

The research presented here offers insight into the heightened challenges of accessing vital
resources during the AIDS epidemic among marginalized PWAs, such as women and IV
drug users. Lessons from the AIDS pandemic have informed much of the recent COVID-19
response and vaccine development, yet disparities affecting exposure rates and treatment
access still exist today which disproportionately affect marginalized communities. In
considering the history of the AIDS crisis, it’s important to look forward and ask, how can we
confront future pandemics in efficient and equitable ways?
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